Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOVXNASDAQ:IMUXNASDAQ:IZTCNASDAQ:OCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOVXGeoVax Labs$0.92+2.7%$1.00$0.73▼$11.18$14.05M3.451.22 million shs12.85 million shsIMUXImmunic$0.75-2.3%$0.93$0.56▼$2.11$71.52M1.48893,859 shs1.19 million shsIZTCInvizyne Technologies$12.81-2.6%$12.72$8.50▼$23.00$80.09MN/A37,647 shs166 shsOCXOncoCyte$3.18+16.3%$2.99$1.92▼$4.75$91.52M0.9759,148 shs100,514 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOVXGeoVax Labs+2.74%-18.89%-9.34%-31.50%-51.33%IMUXImmunic-2.28%-13.79%-21.93%-34.21%-30.56%IZTCInvizyne Technologies0.00%-4.66%-14.83%-18.04%+1,280,999,900.00%OCXOncoCyte-0.78%+20.27%+13.39%-3.79%+18.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGOVXGeoVax Labs3.0921 of 5 stars3.64.00.00.02.51.70.6IMUXImmunic3.4359 of 5 stars3.63.00.00.04.12.50.6IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AOCXOncoCyte1.8897 of 5 stars3.44.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOVXGeoVax Labs 3.29Buy$11.101,100.39% UpsideIMUXImmunic 3.25Buy$11.601,446.67% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/AOCXOncoCyte 2.75Moderate Buy$6.0690.94% UpsideCurrent Analyst Ratings BreakdownLatest GOVX, IZTC, IMUX, and OCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.006/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/21/2025OCXOncoCyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/21/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/13/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.255/2/2025GOVXGeoVax LabsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $9.005/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOVXGeoVax Labs$3.95M3.56N/AN/A$0.48 per share1.93IMUXImmunicN/AN/AN/AN/A$0.20 per shareN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AOCXOncoCyte$3.84M23.63N/AN/A($0.70) per share-4.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOVXGeoVax Labs-$24.99M-$3.65N/AN/AN/A-438.20%-511.96%-286.58%8/5/2025 (Estimated)IMUXImmunic-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)IZTCInvizyne TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AOCXOncoCyte-$60.66M-$3.53N/AN/AN/A-1,516.06%-215.59%-27.23%8/6/2025 (Estimated)Latest GOVX, IZTC, IMUX, and OCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/12/2025Q1 2025OCXOncoCyte-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million5/1/2025Q1 2025GOVXGeoVax Labs-$0.59-$0.45+$0.14-$0.45$0.75 million$1.64 million3/27/2025Q4 2024GOVXGeoVax Labs-$0.79-$0.30+$0.49-$0.30$2.38 million$3.00 million3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOVXGeoVax LabsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOVXGeoVax LabsN/A3.623.62IMUXImmunicN/A0.740.74IZTCInvizyne TechnologiesN/AN/AN/AOCXOncoCyte0.203.743.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOVXGeoVax Labs6.09%IMUXImmunic51.82%IZTCInvizyne TechnologiesN/AOCXOncoCyte55.35%Insider OwnershipCompanyInsider OwnershipGOVXGeoVax Labs1.20%IMUXImmunic4.60%IZTCInvizyne TechnologiesN/AOCXOncoCyte2.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOVXGeoVax Labs1015.19 million15.01 millionNot OptionableIMUXImmunic7095.82 million91.41 millionOptionableIZTCInvizyne Technologies296.25 millionN/AN/AOCXOncoCyte12028.60 million28.01 millionNo DataGOVX, IZTC, IMUX, and OCX HeadlinesRecent News About These CompaniesOncocyte Exits Irvine, Rebrands as Insight Molecular DiagnosticsJune 18 at 2:56 AM | ocbj.comOncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to NashvilleJune 17 at 7:00 AM | globenewswire.comAWM Investment Company Inc. Has $1.85 Million Position in OncoCyte Co. (NASDAQ:OCX)May 23, 2025 | marketbeat.comOncocyte Corp. Adjusts Pricing for GraftAssureCore™ Assay to $2,753, Enhancing Market Opportunities and Reimbursement PotentialMay 21, 2025 | nasdaq.comOncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 20, 2025 | finanznachrichten.deMedicare Boosts Reimbursement for Oncocyte’s Flagship TechnologyMay 19, 2025 | finance.yahoo.comMedicare Boosts Reimbursement for Oncocyte's Flagship TechnologyMay 19, 2025 | globenewswire.comOncocyte Corporation: Oncocyte Reports Q1 2025 Results and Business ProgressMay 13, 2025 | finanznachrichten.deOncoCyte targets 20 transplant center milestone and upcoming FDA submission while advancing rebranding initiativeMay 13, 2025 | msn.comOncoCyte Corporation (OCX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comOncocyte Reports Q1 2025 Results and Business ProgressMay 12, 2025 | globenewswire.comOncoCyte Q1 2025 Earnings PreviewMay 11, 2025 | msn.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | globenewswire.comOncocyte to Release First Quarter 2025 Results on May 12, 2025May 7, 2025 | prismmediawire.comWhy OncoCyte Corporation’s (OCX) Stock Is Up 5.11%May 7, 2025 | aaii.comBest Momentum Stocks to Buy for May 6thMay 6, 2025 | zacks.comNew Strong Buy Stocks for May 6thMay 6, 2025 | zacks.comOncocyte Corporation: Oncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | finanznachrichten.deOncocyte study links blood test to kidney rejection markersApril 30, 2025 | investing.comOncocyte Provides Positive Update on Clinical Trial ProgressApril 30, 2025 | globenewswire.comOncocyte’s Proprietary Assay Demonstrates Long-Term Clinical ValidityApril 29, 2025 | taiwannews.com.twNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGOVX, IZTC, IMUX, and OCX Company DescriptionsGeoVax Labs NASDAQ:GOVX$0.92 +0.02 (+2.74%) As of 06/18/2025 04:00 PM EasternGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Immunic NASDAQ:IMUX$0.75 -0.02 (-2.28%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.76 +0.01 (+1.20%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Invizyne Technologies NASDAQ:IZTC$12.81 -0.34 (-2.59%) As of 06/13/2025Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.OncoCyte NASDAQ:OCX$3.18 +0.45 (+16.30%) Closing price 06/17/2025 07:21 PM EasternExtended Trading$3.18 0.00 (0.00%) As of 06/17/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
